StockWatch
·
Healthcare Research- Analytics & Technology
Board Meeting29 Apr 2026, 08:41 pm

Indegene Board Approves FY26 Results, Recommends ₹2.25 Dividend

AI Summary

Indegene Ltd's Board of Directors met on April 29, 2026, and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of ₹2.25 per equity share (face value ₹2) for FY26, which will be paid within 30 days of shareholder approval at the upcoming AGM. Additionally, the Board approved allotments under the ESOP Scheme 2020 and RSU Scheme 2020, and sanctioned amendments to nineteen policies in compliance with SEBI regulations, covering areas like material subsidiary, whistle blower, insider trading, related party transactions, and corporate governance.

Key Highlights

  • Board approved audited standalone and consolidated financial results for Q4 and FY26.
  • Recommended a final dividend of ₹2.25 per equity share for the financial year ended March 31, 2026.
  • Approved allotment of shares under ESOP Scheme 2020 and RSU Scheme 2020.
  • Sanctioned amendments to 19 policies, including those related to corporate governance and insider trading.